ABSTRACT:

This Point of View provides an overview of the integrated treatment framework for influenza and COVID-19 in the post-pandemic era. We discuss the available medications for influenza treatment and compare their efficacy. Additionally, we address the issue of antiviral resistance and the safety considerations associated with these medications. The research methods and findings supporting this treatment approach are discussed, highlighting its potential limitations and challenges. This work aims to contribute to the development of effective treatment strategies for influenza and COVID-19, considering the evolving landscape of infectious diseases in the aftermath of the pandemic.

KEYWORDS:

Influenza; post-pandemic; treatment framework;

REFERENCES :

1) World Health Organization. Influenza (Seasonal). Retrieved from

https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2) Centers for Disease Control and Prevention. Influenza (Flu). Retrieved from

https://www.cdc.gov/flu/index.htm
3) Hayden FG, et al. (2018). Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), 913-923.
4) U.S. Food and Drug Administration. (2018). Xofluza (baloxavir marboxil) tablets, for oral use. Retrieved from

https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/ 210854s000lbl.pdf
5) Harvard Health Publishing. (2019, January 2). Baloxavir (Xofluza): A new antiviral drug for the flu. Retrieved from https://www.health.harvard.edu/blog/baloxavir-xofluza-a-new-antiviral-drug-for-the-flu-2019010215672
6) Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013). Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research, 100(2), 446–454. https://doi.org/10.1016/j.antiviral.2013.09.015.
7) Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Jul;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007.
8) Hayden, F. G., Osterhaus, A. D., Treanor, J. J., Fleming, D. M., Aoki, F. Y., Nicholson, K. G., Bohnen, A. M., Hirst, H. M., Keene, O., & Wightman, K. (1997). Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. The New England journal of medicine, 337(13), 874–880. https://doi.org/10.1056/NEJM199709253371302.
9) U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. Accessed May 28, 2023.
10) Neumann, G., & Kawaoka, Y. (2019). Predicting the Next Influenza Pandemics. The Journal of Infectious Diseases, 219(Supplement_1), S14–S20. doi: 10.1093/infdis/jiz040.
11) U.S. Food and Drug Administration. Relenza (zanamivir) inhalation powder for oral inhalation use. Accessed May 28, 2023.
12) Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis. 2012;12(3):240-248. doi: 10.1016/S1473-3099(11)70318-8
13) Zhang W, Jing W, Xie Y, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2020;4(4):CD008965. doi: 10.1002/14651858.CD008965.pub4
14) Terrier, O., & Slama-Schwok, A. (2021). Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. In X. Liu, P. Zhan, L. Menendez-Arias, & V. Poongavanam (Eds.), Antiviral Drug Discovery and Development (pp. 195–218). Springer Singapore. doi: 10.1007/978-981-16-0267-2_8.
15) Bright RA, Medina MJ, Xu X, et al. Incidence of Adamantane Resistance Among Influenza A (H3N2) Viruses Isolated Worldwide From 1994 to 2005: A Cause for Concern. Lancet. 2005 Dec 17;366(9492):1175-1181. doi: 10.1016/S0140-6736(05)67338-2.
16) Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197.
17) Ison, M. G., Portsmouth, S., Yoshida, Y., Shishido, T., Mitchener, M., Tsuchiya, K., Uehara, T., & Hayden, F. G. (2020). Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. The Lancet. Infectious diseases, 20(10), 1204–1214. https://doi.org/10.1016/S1473-3099(20)30004-9.
18) Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020 Jul;6(10):1192-1198. doi: 10.1016/j.eng.2020.03.007.
19) U.S. Food and Drug Administration. Tamiflu (oseltamivir phosphate) capsules and for oral suspension. Accessed May 28, 2023.
20) U.S. Food and Drug Administration. Relenza (zanamivir) inhalation powder for oral inhalation use. Accessed May 28, 2023.
21) Bright RA, Medina MJ, Xu X, et al. Incidence of Adamantane Resistance Among Influenza A (H3N2) Viruses Isolated Worldwide From 1994 to 2005: A Cause for Concern. Lancet. 2005 Dec 17;366(9492):1175-1181. doi: 10.1016/S0140-6736(05)67338-2.
22) Carrat F, Flahault A. Influenza Vaccine: The Challenge of Antigenic Drift. Vaccine. 2007 Nov 16;25(43):6852-6862. doi: 10.1016/j.vaccine.2007.07.027.
23) Takashita E, Morita H, Ogawa R, et al. Susceptibility of Influenza Viruses to the Novel Cap-Dependent Endonuclease Inhibitor Baloxavir Marboxil. Front Microbiol. 2019 Jan 10;9:3026. doi: 10.3389/fmicb.2018.03026.
24) Hurt A. C. (2014). The epidemiology and spread of drug resistant human influenza viruses. Current opinion in virology, 8, 22–29.

https://doi.org/10.1016/j.coviro.2014.04.009.
25) Opatowski, L., Fraser, C., Griffin, J., de Lamballerie, X., et al. (2018). Influenza interaction with cocirculating pathogens and its impact on surveillance, pathogenesis, and epidemic profile: A key role for mathematical modelling. PLoS Pathogens, 14(2), e1006770. doi: 10.1371/journal.ppat.1006770.
26) World Health Organization. Global Influenza Surveillance and Response System (GISRS) Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza. Accessed May 28, 2023.
27) Lackenby A, Besselaar TG, Daniels RS, et al. Global Update on the Susceptibility of Human Influenza Viruses to Neuraminidase Inhibitors, 2014-2015. Antiviral Res. 2016 Feb;132:178-185. doi: 10.1016/j.antiviral.2016.06.001.
28) Hayden, F. G., Sugaya, N., Hirotsu, N., et al. (2018). Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. New England Journal of Medicine, 379(10), 913-923. doi: 10.1056/NEJMoa1716197.
29) European Medicines Agency. (Accessed 2023, May 28). Xofluza Summary of Product Characteristics.
30) Chiu, M. N., Bhardwaj, M., & Pilkhwal Sah, S. (2022). Safety profile of COVID-19 drugs in a real clinical setting. European Journal of Clinical Pharmacology, 78(5), 733-753. doi: 10.1007/s00228-021-03270-2.
31) Medicines.org.uk. (Accessed 2023, May 28). Favipiravir Summary of Product Characteristics.
32) Roche Products Limited. (Accessed 2023, May 28). Tamiflu Summary of Product Characteristics.
33) Ehrenstein, V., Kristensen, N. R., Monz, B. U., Clinch, B., Kenwright, A., & Sorensen, H. T. (2018). Oseltamivir in pregnancy and birth outcomes. BMC Infectious Diseases, 18(1), 519. doi: 10.1186/s12879-018-3423-z
34) GlaxoSmithKline UK. (Accessed 2023, May 28). Relenza Summary of Product Characteristics.
35) European Medicines Agency. (Accessed 2023, May 28). Zanamivir Summary of Product Characteristics.
36) Taieb, V., Ikeoka, H., Wojciechowski, P., Jablonska, K., Aballea, S., Hill, M., & Hirotsu, N. (2021). Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients – a Bayesian network meta-analysis. Current medical research and opinion, 37(2), 225–244. https://doi.org/10.1080/03007995.2020.1839400
37) Drugs.com. (n.d.). Amantadine Side Effects: Common, Severe, Long Term. Retrieved from https://www.drugs.com/sfx/amantadine-side-effects.html
38) Mayo Clinic. (2021, September 1). Amantadine (Oral Route): Side Effects. Retrieved from

https://www.mayoclinic.org/drugs-supplements/amantadine-oral-route/side-effects/drg-20061695
39) Danysz, W., Dekundy, A., Scheschonka, A., & Riederer, P. (2021). Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials. Journal of Neural Transmission, 128(1), 127-169. doi: 10.1007/s00702-021-02306-2.
40) Tırmıkçıoğlu Z. (2022). Favipiravir exposure and pregnancy outcome of COVID-19 patients. European Journal of Obstetrics & Gynecology and Reproductive Biology, 268, 110-115. doi: 10.1016/j.ejogrb.2021.12.001.
41) Ping, Y. H., Yeh, H., Chu, L. W., Lin, Z. H., Hsu, Y. C., Lin, L. C., … Lin, T. Y. (2022). The Traditional Chinese Medicine Formula Jing Guan Fang for Preventing SARS-CoV-2 Infection: From Clinical Observation to Basic Research. Frontiers in Pharmacology, 13, 744439. doi: 10.3389/fphar.2022.744439.